Home › Trial NCT04806035
Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia
- Trial IDNCT04806035
- StatusTerminated
- PhasePhase 1
- Study typeInterventional
- SponsorTG Therapeutics, Inc.
- Enrollment21
- Start date2021-04-28
- ConditionsCLL · SLL · Richter's Transformation · Indolent Lymphoma · Follicular Lymphoma · Marginal Zone Lymphoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Human verification coming soon — the enriched analysis will be viewable here.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.